

FORM PTO-1390 (Modified)  
(REV 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES**  
**DESIGNATED/ELECTED OFFICE (DO/EO/US)**  
**CONCERNING A FILING UNDER 35 U.S.C. 371**

0273-0011

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

To Be Determined

10/089503



INTERNATIONAL APPLICATION NO.  
PCT/EP00/09594INTERNATIONAL FILING DATE  
29-September-2000PRIORITY DATE CLAIMED  
30-September-1999

TITLE OF INVENTION

THE PRV-1 GENE AND USE THEREOF

APPLICANT(S) FOR DO/EO/US

PAHL, Heike



Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☒ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

**Items 13 to 20 below concern document(s) or information included:**

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☐ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

1. Statement to Support Filing and Submission of Sequence Listing in Accordance With 37 CFR 1.821-1.825; 2. English language translation of the Reply to the Written Notice containing Amended Claims, dated 15-October-2001; 3. Paper copy of the sequence listing (10 sequences); and 4. Postcard

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) <b>To Be Determined</b>		INTERNATIONAL APPLICATION NO. <b>PCT/EP00/09594</b>		ATTORNEY'S DOCKET NUMBER <b>0273-0011</b>	
-----------------------------------------------------------------------------	--	--------------------------------------------------------	--	----------------------------------------------	--

**24.** The following fees are submitted:

BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5)) :			CALCULATIONS PTO USE ONLY	
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO .....	<b>\$1040.00</b>			
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....	<b>\$890.00</b>			
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....	<b>\$740.00</b>			
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....	<b>\$710.00</b>			
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) .....	<b>\$100.00</b>			
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>			<b>\$890.00</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than _____ months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30			<b>\$130.00</b>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	11 - 20 =	0	x \$18.00	<b>\$0.00</b>
Independent claims	8 - 3 =	5	x \$84.00	<b>\$420.00</b>
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>	<b>\$0.00</b>
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$1,440.00</b>
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				<b>\$0.00</b>
<b>SUBTOTAL =</b>				<b>\$1,440.00</b>
Processing fee of <b>\$130.00</b> for furnishing the English translation later than _____ months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30 +				<b>\$0.00</b>
<b>TOTAL NATIONAL FEE =</b>				<b>\$1,440.00</b>
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).			<input type="checkbox"/>	<b>\$0.00</b>
<b>TOTAL FEES ENCLOSED =</b>				<b>\$1,440.00</b>
			<b>Amount to be refunded</b>	\$
			<b>charged</b>	\$

a. ☒ A check in the amount of **\$1,440.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **50-0622**. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

**SEND ALL CORRESPONDENCE TO:**

**SHANKS & HERBERT**  
 TransPotomac Plaza  
 1033 North Fairfax Street, Suite 306  
 Alexandria, VA 22314  
 (703) 683-3600  
 (703) 683-9875 (facsimile)

SIGNATURE  
**Toni-Junell Herbert**  
 NAME  
**34,348**  
 REGISTRATION NUMBER  
3/29/02  
 DATE

In re Application of: PAHL

**Appl. No.: To Be Determined (U.S. National Stage of PCT/EP00/09594)**

Filed: Herewith

International Filing Date: September 29, 2000

For: The PRV-1 Gene and Use Thereof

**Art Unit: To Be Determined**

**Examiner: To Be Determined**

Atty. Docket: 0273-0011

**STATEMENT TO SUPPORT FILING AND SUBMISSION OF SEQUENCE  
LISTING IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825**

Assistant Commissioner for Patents  
Washington, D.C. 20231  
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that: /

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;
2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same as required by 37 C.F.R. § 1.821(f); and
3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these

Appl. No.: To Be Determined  
(U.S. National Stage of PCT/EP00/09594  
Atty. Docket No.: 0273-0011

10/089503  
JC13 Rec'd PCT/PTC 29 MAR 2002

statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

SHANKS & HERBERT

By: Toni-Junell Herbert  
Toni-Junell Herbert  
Reg. No. 34,348

Date: 3/29/02

TransPotomac Plaza  
1033 N. Fairfax Street  
Suite 306  
Alexandria, VA 22314  
(703) 683-3600

03/06/2003 12:15 FAX 703 683 9875

SHANKS & HERBERT

10/089503 .042902

Rec'd PCT/PTO 06 MAR 2003

10/089503

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: PAHL, Heike

Appl. No.: 10/089,503 (U.S. National Stage of  
PCT/EP00/09594)

Filed: March 29, 2002 (International Filing Date:  
Sept. 29, 2000)

For: **The PRV-1 Gene and Use Thereof**

Art Unit: To Be Assigned

Examiner: To Be Assigned

Atty. Docket: 0273-0011

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants wish to thank Mr. Alverado of the PCT branch for his assistance during the teleconference today, March 5, 2003. During that conversation, Mr. Alverado requested that this preliminary amendment be filed to clarify the status of the claims. Specifically, because the amendment dated April 29, 2002 may have caused some confusion as to the status of the claims, applicants specifically request that the April 29, 2002 amendment not be entered. In its place, this preliminary amendment clarifies that 11 claims, now numbered 25-35, are pending in the application. Prior to examination, applicants respectfully request that the following amendment be entered:

IN THE CLAIMS:

Please cancel claims 1-24.

Please add the following new claims:

U.S. Appl. No: 10/089,503  
(U.S. National Stage of PCT/EP00/09594)  
Atty. Dkt. No: 0273-0011

25. An isolated N-glycosylated polypeptide comprising one of the following amino acid sequences:  
amino acids 1-437 of SEQ ID NO:2;  
amino acids 1-409 of SEQ ID NO:2;  
amino acids 1-401 of SEQ ID NO:2;  
amino acids 22-437 of SEQ ID NO:2;  
amino acids 22-409 of SEQ ID NO:2;  
amino acids 22-401 of SEQ ID NO:2;  
or a biologically active fragment thereof containing at least 50 amino acids; or a biologically active variant thereof.
26. A method for treating pancytopenias and pancytopathies in the bone marrow or blood of a patient, comprising administering to a patient in need thereof an N-glycosylated polypeptide comprising one of the following amino acid sequences:  
amino acids 1-437 of SEQ ID NO:2;  
amino acids 1-409 of SEQ ID NO:2;  
amino acids 1-401 of SEQ ID NO:2;  
amino acids 22-437 of SEQ ID NO:2;  
amino acids 22-409 of SEQ ID NO:2;  
amino acids 22-401 of SEQ ID NO:2;  
or a biologically active fragment thereof containing at least 50 amino acids; or a biologically active variant thereof.
27. A method for treating pancytopenias and pancytopathies in the bone marrow or blood of a patient, comprising administering to a patient in need thereof an N-glycosylated polynucleotide comprising one of the following nucleotide sequences:  
nucleotides 1-1600 of SEQ ID NO:1;  
nucleotides 36-1346 of SEQ ID NO:1;  
nucleotides 36-1262 of SEQ ID NO:1;

U.S. Appl. No: 10/089,503  
(U.S. National Stage of PCT/EP00/09594)  
Atty. Dkt. No: 0273-0011

nucleotides 36-1238 of SEQ ID NO:1;  
nucleotides 39-1346 of SEQ ID NO:1;  
nucleotides 39-1262 of SEQ ID NO:1;  
nucleotides 39-1238 of SEQ ID NO:1;  
nucleotides 99-1346 of SEQ ID NO:1;  
nucleotides 99-1262 of SEQ ID NO:1;  
nucleotides 99-1238 of SEQ ID NO:1;  
or a biologically active fragment thereof; or a biologically active variant thereof;  
wherein the polynucleotide encodes a PRV-1 polypeptide or a functional fragment  
or variant thereof and wherein the patient cell(s) express an effective amount of  
the PRV-1 polypeptide or functional fragment or variant thereof.

28. A method for multiplying endogenous cells and/or established cell lines *ex vivo* or *in vitro*, comprising contacting the cells and/or cell lines with an effective amount of an N-glycosylated polypeptide comprising one of the following amino acid sequences:

amino acids 1-437 of SEQ ID NO:2;  
amino acids 1-409 of SEQ ID NO:2;  
amino acids 1-401 of SEQ ID NO:2;  
amino acids 22-437 of SEQ ID NO:2;  
amino acids 22-409 of SEQ ID NO:2;  
amino acids 22-401 of SEQ ID NO:2;  
or a biologically active fragment thereof comprising at least 50 amino acids; or a  
biologically active variant thereof.

29. A method of inhibiting cell growth *in vivo* or *in vitro*, comprising contacting a cell(s) with a cell growth inhibiting amount of an N-glycosylated polypeptide comprising one of the following amino acid sequences:

amino acids 1-437 of SEQ ID NO:2;  
amino acids 1-409 of SEQ ID NO:2;

U.S. Appl. No: 10/089,503  
(U.S. National Stage of PCT/EP00/09594)  
Atty. Dkt. No: 0273-0011

amino acids 1-401 of SEQ ID NO:2;  
amino acids 22-437 of SEQ ID NO:2;  
amino acids 22-409 of SEQ ID NO:2;  
amino acids 22-401 of SEQ ID NO:2;  
or a biologically active fragment thereof comprising at least 50 amino acids; or a  
biologically active variant thereof.

30. The method of claim 29, wherein the polypeptide functions as a cytostatic agent.
31. A method for treating a proliferative disease in a patient, comprising administering to a patient in need thereof an N-glycosylated polypeptide comprising one of the following amino acid sequences:  
amino acids 1-437 of SEQ ID NO:2;  
amino acids 1-409 of SEQ ID NO:2;  
amino acids 1-401 of SEQ ID NO:2;  
amino acids 22-437 of SEQ ID NO:2;  
amino acids 22-409 of SEQ ID NO:2;  
amino acids 22-401 of SEQ ID NO:2;  
or a biologically active fragment thereof comprising at least 50 amino acids; or a  
biologically active variant thereof.
32. The method of claim 31, wherein the proliferative disease is selected from the group consisting of: a myeloproliferative disease, polycythemia rubra vera, essential thrombocythemia, myelofibrosis, CML, leukemia, a lymphoma and a solid tumor.
33. A method of inhibiting cell growth, comprising contacting a cell(s) with a polynucleotide comprising one of the following nucleotide sequences:  
nucleotides 1-1600 of SEQ ID NO:1;  
nucleotides 36-1346 of SEQ ID NO:1;



U.S. Appl. No: 10/089,503  
(U.S. National Stage of PCT/EP00/09594)  
Atty. Dkt. No: 0273-0011

nucleotides 36-1262 of SEQ ID NO:1;  
nucleotides 36-1238 of SEQ ID NO:1;  
nucleotides 39-1346 of SEQ ID NO:1;  
nucleotides 39-1262 of SEQ ID NO:1;  
nucleotides 39-1238 of SEQ ID NO:1;  
nucleotides 99-1346 of SEQ ID NO:1;  
nucleotides 99-1262 of SEQ ID NO:1;  
nucleotides 99-1238 of SEQ ID NO:1;

or a biologically active fragment thereof; or a biologically active variant thereof;  
wherein the polynucleotide encodes a PRV-1 polypeptide or a functional fragment or  
variant thereof and wherein the cell(s) express a growth inhibiting amount of the PRV-1  
polypeptide or functional fragment or variant thereof.

34. A method for treating a proliferative disease in a patient, comprising  
administering to a patient in need thereof an N-glycosylated polynucleotide  
comprising one of the following nucleotide sequences:

nucleotides 1-1600 of sequence No. 1;  
nucleotides 36-1346 of sequence No. 1;  
nucleotides 36-1262 of sequence No. 1;  
nucleotides 36-1238 of sequence No. 1;  
nucleotides 39-1346 of sequence No. 1;  
nucleotides 39-1262 of sequence No. 1;  
nucleotides 39-1238 of sequence No. 1;  
nucleotides 99-1346 of sequence No. 1;  
nucleotides 99-1262 of sequence No. 1;  
nucleotides 99-1238 of sequence No. 1;

or a biologically active fragment thereof; or a biologically active variant thereof;  
wherein the polynucleotide encodes a PRV-1 polypeptide or a functional fragment or  
variant thereof and wherein the patient cell(s) express an effective amount of the PRV-1  
polypeptide or a functional fragment or variant thereof.

U.S. Appl. No: 10/089,503  
(U.S. National Stage of PCT/EP00/09594)  
Atty. Dkt. No: 0273-0011

35. The method of claim 34, wherein the proliferative disease is selected from the group consisting of: a myeloproliferative disease, polycythemia rubra vera, essential thrombocythemia, myelofibrosis, CML, leukemia, a lymphoma and a solid tumor.


#### REMARKS

Claims 25-35 are pending in the above-identified application. Claims 1-24 have been canceled. Support for new claims 25-35 is found in canceled claims 1-24 and in the specification (English translation) at, for example, pages 12-14. No new matter has been added.

Applicant respectfully asserts that the application is now in condition for examination.

Respectfully submitted,

SHANKS & HERBERT

By:   
Shelly Guest Cermak  
Reg. No. 39,571

Date: 3-5-03

TransPotomac Plaza  
1033 N. Fairfax Street  
Suite 306  
Alexandria, VA 22314  
(703) 683-3600

10/089503 10/089503  
Rec'd PCT/PTO 29 APR 2002

10/089503

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Pahl, Heike

Serial No. 10/089,503 (U.S. National Stage of  
PCT/EP00/09594

Filed: March 29, 2002 (International Filing Date:  
Sept. 29, 2000

For: The PRV-1 Gene and Use Thereof

Art Unit: To Be Assigned

Examiner: To Be Assigned

Atty. Docket: 0273-0011

**AMENDMENT AND SUBMISSION OF SEQUENCE LISTING  
UNDER 37 C.F.R. § 1.825(a)**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. § 1.825(a), Applicants submit substitute sheets to  
amend the paper copy of the Sequence Listing.

**In the Specification:**

Please cancel the existing Sequence Listing for the above-identified application,  
and replace it with the substitute sheets appended hereto.

**REMARKS**

Applicants' Attorney hereby states that the submission, filed in accordance with  
37 C.F.R. § 1.825(a), does not include new matter. Applicants' undersigned attorney has

amended the specification only to direct the entry of this corrected Sequence Listing between the specification and the claims of the above-identified application.

✓ In accordance with 37 C.F.R. 1.825(b), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith are the same.

Support for the new Sequence Listing is found in the canceled Sequence Listing found between the specification and claims of the above-identified application.

This amendment and submission is totally responsive to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US). The Notice also requests an Oath or Declaration of the inventors. The Oath and Declaration were filed in the United States Patent and Trademark Office on April 20, 2002.

It is respectfully believed this application is now in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

SHANKS & HERBERT

By:



Toni-Junell Herbert

Reg. No. 34,348

Date:

9/20/02

TransPotomac Plaza  
1033 N. Fairfax Street  
Suite 306  
Alexandria, VA 22314  
(703) 683-3600

2/plyb

---

The gene PRV-1 and its use

---

Description

5           The invention relates to a nucleotide sequence  
which encodes the PRV-1 gene, to recombinant DNA which  
contains this nucleotide sequence, to vectors which  
contain the recombinant DNA and to cells which are  
transformed with these vectors, and also to a PRV-1  
10 polypeptide, to antibodies against this polypeptide, to  
a process for detecting the PRV-1 polypeptide and to  
drugs which comprise the PRV-1 polypeptide or  
antibodies which are directed against the PRV-1  
polypeptide.

15           Polycythemia rubra vera (erythremia), also  
termed polycythemia vera or p. vera, is a malignant  
hematological disease in which there is an increased  
formation of erythroid, granulocytic and megakaryocytic  
cells. The disease is of clonal origin and arises as a  
20 result of the mutation of a single hematopoietic  
precursor cell. In Germany, the incidence of p. vera is  
from 4 to 6 per million inhabitants. If left untreated,  
the disease leads to death within 18 months. Treatment  
by means of blood-letting or chemotherapy extends the  
25 average survival time to more than 13 years.

P. vera is diagnosed by means of clinical  
criteria. The clinical picture includes headaches,  
pruritus, splenomegaly in two thirds of the patients,  
bleeding or thromboses, hypertension in a third of the  
30 patients, gout, which is brought about by an increase  
in the production of uric acid, and, in some cases,  
septic ulcers. The most important laboratory finding is  
an increase in the values for hemoglobin, hematocrit,  
erythrocyte count and total erythrocyte volume, and  
35 also a neutrophilic granulocytosis or thrombocytosis in  
many cases. Since, on the one hand, most of the  
criteria are rather diffuse and, on the other hand, not  
all the patients fulfill these criteria, it is

frequently difficult to distinguish p. vera from other myeloproliferative diseases, such as chronic granulocytic leukemia or essential thrombocytosis, and thereby confirm the diagnosis. To date, the molecular  
5 cause of p. vera is completely unknown. Since, however, p. vera takes a severe course if it is not treated, accurate diagnosis is important.

An object of the invention was therefore to find the molecular cause of polycythemia rubra vera and  
10 to create the possibility of diagnosing it.

This object was achieved by isolating a gene which is expressed specifically in association with p. vera and not in healthy control individuals. This gene is designated the PRV-1 gene (polycythemia rubra vera).

15 A similar nucleotide sequence is disclosed in International application WO 98/50552.

One part of the subject matter of the invention therefore relates to a polynucleotide which encodes the PRV-1 gene and essentially comprises the sequence ID  
20 No. 1. The polynucleotides of the present invention can be single-stranded or double-stranded DNA or RNA. If they are RNA, it is then clear to the skilled person that "U" nucleotides are present in place of "T" nucleotides. "Polynucleotide" is understood as meaning  
25 nucleic acids which contain 15 or more nucleotides.

The nucleotide sequence according to the invention is depicted in figure 1. The invention therefore relates to a polynucleotide which corresponds to the sequence shown in figure 1 and also to a  
30 polynucleotide whose nucleotide sequence exhibits minor differences. Within the meaning of the present application, minor differences are understood as meaning those sequences in which a few, preferably not more than 50 and particularly preferably not more than  
35 25, nucleotides can be exchanged, with, however, the function of the gene encoded by the nucleotide sequence being unaffected. The skilled person is familiar with the fact that a base triplet encoding an amino acid can be replaced with another triplet which encodes the same

amino acid. In addition to this, regions which are of less importance can be deleted and/or mutated to a minor extent. In a particular embodiment, the polynucleotide comprises nucleotides 36 to 1346 of sequence No. 1, that is the coding region of the PRV-1 gene. Other embodiments comprise nucleotides 36 to 1262 or 36 to 1238 of sequence No. 1. This region presumably encodes the active region of the PRV-1 polypeptide. Finally, the polynucleotide of the invention can also comprise nucleotides 39 to 1346, 39 to 1262 or 39 to 1238 of sequence No. 1, such that the codon which encodes the starting methionine is not present. A preferred embodiment is a polynucleotide which comprises nucleotides 99 to 1346, 99 to 1262 or 99 to 1238 of sequence No. 1. This results in the codons at the 5' end which encode the signal peptide of the PRV-1 polypeptide not being present.

The polynucleotide according to the invention can also be a fragment of the PRV-1 gene. As a rule, the fragment possesses more than 100 nucleotides, preferably, however, more than 300 nucleotides. The fragments can also be used as primers or as probes, in particular for PCR; in this case, the fragments can be truncated to fit the purpose. Usually, primers have a length of between 10 and 30 nucleotides and probes have a length of between 15 and 50 nucleotides.

The PRV-1 gene is an endogenous gene whose expression in healthy individuals is, however, restricted to only a few organs. Normally, it is expressed in the main in the hematopoietic organs, i.e. in bone marrow and fetal liver, and weakly expressed in the spleen, but not expressed in heart, muscle, pancreas or kidney. In patients who are suffering from p. vera, this gene is very strongly overexpressed in the hematopoietic cells, in particular.

The PRV-1 gene encodes a protein which exhibits the protein sequence shown in Figure 2. The signal peptide, which is present in the protein sequence of all surface molecules and normally removed when the

5

10

25

35



been conclusively elucidated, it is frequently observed that GPI-linked proteins are also released into the medium. This is referred to as "shedding". To date, it has not been clarified whether this is a specific process, i.e. such proteins are cleaved from the membrane by enzymes in a controlled manner, or whether it represents a non-specific loss of the anchor. It is consequently very probable that PRV-1 is to be found both on the cell membrane and extracellularly. The secreted form, which is not membrane-bound, is probably more important for the effect of the polypeptide as a growth factor and growth inhibitor since, as a growth factor, this form is able to diffuse and reach other cells.

It is clear to the skilled person that he can influence the attachment of the protein to the cell membrane by manipulating these C-terminal amino acids. This particularly concerns the preparation of defined DNA constructs which are intended for expressing the PRV-1 polypeptide or fragments of this polypeptide. The codons which encode these amino acids can be mutated or deleted.

The gene encodes a surface receptor of the uPAR/Ly6 family. This receptor family can transduce mitogenic signals, i.e. signals which stimulate cell division. It is therefore assumed that overexpression of the PRV-1 gene, inter alia on the bone marrow cells of p. vera patients, contributes to hyperproliferation of these cells.

It has been found that PRV-1 is not expressed on granulocytes in healthy individuals or in patients suffering from other myeloproliferative diseases, e.g. suffering from chronic granulocytic leukemia, acute granulocytic leukemia, essential thrombocytosis or secondary erythrocytosis.

In order to be able to use the polypeptide encoded by the PRV-1 gene for analyses and detection methods, it is expediently generated from recombinant DNA, with the recombinant DNA preferably comprising the

nucleotide sequence ID No. 1 or at least the coding region of the PRV-1 gene, that is nucleotides 36 to 1346 of sequence ID No. 1, or else at least nucleotides 39 to 1262 or 39 to 1238, functionally linked to a promoter. However, the recombinant DNA can also  
5 comprise only a fragment of sequence No. 1.

The invention furthermore relates to a vector which contains the recombinant DNA for the PRV-1 polypeptide, or a fragment thereof, and to a host cell  
10 which is transfected or transformed with this vector. The host cells may be prokaryotic, for example bacteria such as E. coli. However, the polypeptides which are expressed are then not glycosylated. Preference is therefore given to eukaryotic host cells, which are  
15 able to glycosylate the expressed protein post-translationally and modify it in other ways. Examples of eukaryotic host cells are insect cells, such as Sf9 cells, for expression following infection with recombinant baculoviruses, and mammalian cells, such as  
20 293 cells, COS cells, CHO cells and HeLa cells. These examples are not exhaustive. It is also possible to use yeast cells as host cells. It is clear to the skilled person that the glycosylation pattern can differ depending on the host cell. The biological activity of  
25 the expression product can therefore also vary. Particular preference is given to host cells which glycosylate the expression product in such a way that the biological activity of the protein is retained.

Another aspect of the invention is a process  
30 for preparing a polypeptide according to the invention. In this process, a DNA encoding the polypeptide according to the invention is caused to be expressed in a host cell. The culture medium or the cells is/are employed for the subsequent isolation of the  
35 polypeptide depending on whether the expressed polypeptide is secreted by the host cell into the culture medium or remains in the cell. After that, the polypeptide according to the invention is concentrated and/or purified using methods which are known in the

state of the art, for example chromatographic methods. Methods for purifying proteins are described, for example, in Scopes, R., Protein Purification: Principles and Practice (3rd edition), Springer Verlag  
 5 (1994). In one particular embodiment, the process according to the invention encompasses the step in which glycosylated polypeptide is concentrated and/or purified. This step can take place either before the polypeptide according to the invention has been  
 10 essentially purified or after it has already been essentially purified. In the latter case, the glycosylated moiety of the purified polypeptide is then separated off and isolated. In the most preferred embodiment of the process, N-glycosylated polypeptide  
 15 is specifically isolated. In another embodiment of the process, polypeptide is isolated which is glycosylated at at least one of the amino acids Asn-46, Asn-189 and Asn-382 of sequence No. 2.

The PRV-1 polypeptide which is isolated from  
 20 granulocytes or produced recombinantly can be employed both for diagnosing polycythemia vera and for treating the disease.

One therapeutic possibility is that of "antisense therapy". This method employs an "antisense"  
 25 RNA molecule, that is an RNA which is complementary to the PRV RNA. Since the PRV-1 RNA has the sequence 5'-AAAAGCAGAAAGAGATTACCAGCC-3' (seq. ID No. 3) at its beginning, the requisite antisense RNA directed against this sequence would possess the following nucleotide  
 30 sequence: 5'-GGCTGGTAATCTCTTTCTGCTTTT-3' (seq. ID No. 4). This antisense RNA is incorporated into a vector and introduced into the p. vera cells. This RNA is introduced, for example, by means of transfection, with the vector used for the transfection preferably being  
 35 configured such that it is introduced specifically into the p. vera cells. Expression of the antisense RNA results in it no longer being possible for the PRV-1 mRNA to be translated into a polypeptide. Cells which







which can be used as probes in the Northern blot, can be prepared by digesting the gene with restriction endonucleases. If the fragments are derived from the cDNA, they are then present as double strands which have to be separated into the single strands for the hybridization. Suitable examples are the Bam HI-PstI fragment from base pair 420 to base pair 831, or the PstI-PstI fragment from base pair 831 to base pair 1900.

PRV-1 mRNA, and consequently the expression of PRV-1, can also be detected by first of all reverse-transcribing the mRNA in an RT-PCR reaction and then amplifying the cDNA; the amplified DNA is then detected with a probe in a hybridization method.

In the case of a positive diagnosis, the disease has to be treated since it otherwise leads to death within a relatively short period of time. For this treatment, it is possible to use specific antibodies which are directed against PRV-1 and to which cytotoxic components can be bonded, where appropriate.

The invention therefore furthermore relates to a drug which, in addition to the customary excipients, comprises antibodies which are directed against the PRV-1 receptor.

Since the PRV-1 receptor is overexpressed in p. vera, many antibodies are bound on the surface of the affected granulocytes when they come into contact with the anti-PRV-1 antibody. The binding of many antibodies to these cells stimulates the immunological cells to destroy these granulocytes. In this way, it is possible to eliminate the p. vera cells specifically.

Surprisingly, it has also been found that the PRV-1 polypeptide exhibits haematopoietic activity. The PRV-1 polypeptide is able to stimulate certain hematopoietic precursor cells to form erythroid colonies. It is particularly the N-glycosylated PRV-1 polypeptides which display this function. The polypeptides according to the invention which are

preferred are therefore the N-glycosylated PRV-1 polypeptides, and fragments thereof, which display the growth factor activity.

Another aspect of the invention is therefore a  
5 drug which, in addition to a pharmaceutically tolerated excipient, comprises the PRV-1 polypeptide or a biologically active fragment thereof. The PRV-1 polypeptide is preferably glycosylated PRV-1 polypeptide and, even more preferably, N-glycosylated  
10 PRV-1 polypeptide or a biologically active fragment thereof. The invention also relates to drugs which comprise at least one polynucleotide according to the invention.

The present invention furthermore relates to  
15 the use of PRV-1 polypeptide, or a biologically active fragment thereof or a biologically active variant thereof, as a growth factor in vivo and ex vivo. The PRV-1 polypeptide, or a biologically active fragment thereof or a biologically active variant thereof, can  
20 be used for treating all pancytopenias and pancytopathies in the bone marrow and in the circulation (change in the cellular constituents of the peripheral blood and bone marrow). The polypeptides of the present invention can, for example, be used for  
25 treating anemias in the case of kidney failure, chemotherapy or whole body radiation, for treating neutropenias and thrombocytopenias during chemotherapy or whole body radiation, for the ex-vivo treatment of peripheral or bone marrow stem cells for expansion  
30 (multiplication) and retransfusion into the patients, and for treating sepsis, systemic inflammatory response syndrome (SIRS) or regional inflammatory reactions. The polypeptides of the present invention, or drugs which comprise them, can be administered in a wide variety of  
35 ways. The forms of administration comprise intravenous, intramuscular, subcutaneous, intraperitoneal, oral, transdermal and transmucosal administration.

The polynucleotides according to the invention can also be used for treating pancytopenias and



pancytopathies. In this case, the aim is to express a PRV-1 polypeptide, or a functional fragment thereof, in cells of the affected patient. Gene therapy methods are first and foremost used in this connection. Cells can  
5 be isolated from the patient and transfected with a polynucleotide according to the invention (ex-vivo manipulation), after which they are then returned to the patient. It is also possible to conceive of methods in which the polynucleotides according to the invention  
10 gain access into the target cells by means of viral transfer. Expression of the inserted nucleic acids then leads to haematopoietic activity.

Surprisingly, it was also found that, at higher concentration, the PRV-1 polypeptide has an inhibitory  
15 effect on the growth of cells. Thus, it was observed, for example, that adding an increased quantity of PRV-1 protein virtually completely stops the formation of erythroid and granulocytic/monocytic colonies. This effect resembles the action of Interferon- $\alpha$ , which is  
20 used, inter alia, therapeutically in chronic myeloid leukemia (CML) and in p. vera. An endogenous inhibitory substance possesses great advantages as compared with a chemical cytostatic agent, such as hydroxyurea, which was used when Interferon- $\alpha$  was not yet available and is  
25 to some extent still used. A disadvantage of Interferon- $\alpha$  is that this active compound has very severe side effects. The patients feel as if they were suffering from a serious influenza. The present invention makes available a hematopoiesis-inhibiting  
30 substance, with the inhibitory activity being concentration-dependent.

Another aspect of the invention is therefore the use of a PRV-1 polypeptide, as described in this application, for inhibiting the growth of cells, in  
35 particular its use as a cytostatic agent. Preference is given to the polypeptide being used for inhibiting the growth of hematopoietic cells. The invention also relates to the use of a polypeptide according to the invention for producing a drug for treating

proliferative diseases. These diseases are, in particular, the myeloproliferative diseases, p. vera, essential thrombocythemia, myelofibrosis, CML and also all leukemias and lymphomas and also solid tumors.

5 Another aspect of the invention is the use of a polynucleotide, as described in this application, of a biologically active fragment or of a biologically active variant thereof, for inhibiting the growth of cells. The polynucleotide can be incorporated into a  
10 suitable vector and transfected into suitable target cells. After the PRV-1 polypeptide, or a biologically active fragment thereof, or a biologically active variant thereof, has been expressed in an appropriate concentration, the growth-inhibiting effect comes into  
15 operation. In the same way, the polynucleotide can be incorporated into a viral vector, after which appropriate target cells are infected virally, leading to PRV-1 being expressed. The invention also relates to the use of a polynucleotide of this application for  
20 producing a drug for treating proliferative diseases, such as the myeloproliferative diseases, p. vera, essential thrombocythemia, myelofibrosis, CML and also all leukemias and lymphomas and also solid tumors.

The invention also relates to kits for  
25 detecting either polycythemia vera or disturbances of the hematopoietic system. These kits comprise a polynucleotide according to the invention and/or a polypeptide according to the invention and/or one or more antibodies according to the invention. In addition  
30 to this, the kit can also comprise a container or compositions which are suitable for implementing detection reactions. Examples of such compositions are buffer solutions, reagents for blocking membranes, hybridization solutions, secondary antibodies,  
35 substrate solutions for detection reactions, etc. The kit is preferably used for implementing PCR reactions, RT-PCR, Northern blots, Southern blots, Western blots and ELISA, RIA or similar reactions.









vector, without pKAT, no retroviruses are then formed. The cell culture medium then only contains the soluble protein produced by the cells. Medium which is derived from pOS-PRV-1-transfected cells, and which does not  
 5 contain any retrovirus, is mixed with CFU-Es and the whole is plated out in the methyl cellulose medium; the resulting colonies are then counted.

The following results were obtained:

10 Table 2: Solubility of PRV-1. The figures in each case indicate the number of colonies.

	Mixture 1	Mixture 2	Mixture 3	Mixture 4
	un- transfected	empty vector (pOS)	GFP (pOS-GFP)	PRV-1 (pOS-PRV-1)
Experiment 4		137	187	557

In this experiment, too, CFU-Es which were  
 15 treated with PRV-1-containing medium formed very many more hematopoietic colonies than did control cells. It can be concluded from this result that PRV-1 is a soluble growth factor.

#### 20 Example 4

PRV-1 also has an inhibitory, cytostatic effect.

The experiments were carried out on peripheral  
 25 blood cells. Since a small number of precursor cells are also circulating in the peripheral blood in healthy individuals, it is possible to culture hematopoietic colonies from peripheral blood cells in a suitable medium (methyl cellulose). 40 ml of peripheral venous  
 30 blood were withdrawn from a healthy donor (while initially introducing heparin or EDTA as an anticoagulant). 15 ml of Ficoll/Hypaque were added to the blood and the mixture was centrifuged at 1 600 rpm for 40 minutes without braking. This results in the  
 35 production of a density gradient which fractionates the





IMDM medium, which had been incubated for 48 hours with untransfected cells (293), or in medium which had been incubated for 48 hours with cells which were expressing the altered PRV-1 (293-GPI-less-PRV-1). The ability of these cells to form hematopoietic colonies was then investigated. The number of erythroid (red) and myeloid (white) blood cell colonies was determined after 14 days. The experiment was repeated three times and also carried out on different days and using different blood donors. Duplicates were also evaluated within the experiment. The following results were obtained:

Experiment 1

Cell supernatant	Donor 1		Donor 2	
	Red colonies	White colonies	Red colonies	White colonies
293	248/221	70/114	127/161	25/66
293-GPI-less-PRV-1	7/3	0/0	31/19	0/0

Experiment 2

Cell supernatant	Donor 1		Donor 2	
	Red colonies	White colonies	Red colonies	White colonies
293	99/91	20/19	49/33	8/1
293-GPI-less-PRV-1	0/0	0/0	0/0	0/0

Experiment 3

Cell supernatant	Donor 1		Donor 2	
	Red colonies	White colonies	Red colonies	White colonies

- 22 -

293	107/207	22/30	24/32	5/8
293-GPI-less- PRV-1	4/3	0/6	0/1	3/0

It can be concluded from this data that a higher dose of PRV-1 than that used in example 3 possesses a cytostatic effect.

5

#### Example 5

The growth factor PRV-1 is N-glycosylated

10 Granulocytes were isolated from a patient suffering from p. vera, and protein extracts were prepared from these cells using a standard protocol. These protein extracts were treated in accordance with the protocol for the "N-Glycosidase F Deglycosylation  
15 Kit" supplied by Boehringer Mannheim. In detail, this means that a "denaturation buffer" was added to the protein extracts and the mixtures were heated at 95°C for 3 minutes, after which they were treated either with "reaction buffer" or with "reaction buffer" plus  
20 N-glycosidase. Each mixture was incubated overnight at 37°C and the proteins were analyzed on a PAGE gel electrophoresis followed by a Western blot. The PRV-1 protein was detected with an antibody directed against a protein having the amino acid sequence ID No. 5. The  
25 results show that while PRV-1 protein purified from granulocytes is 60-65 kDa in size, it is only 40 kDa in size after having been digested with N-glycosidase. This clearly proves that PRV-1 is glycosylated on asparagine residues (asparagine = N).

Freiburg University Hospital Complex

**Patent claims**

- 5 1. An N-glycosylated polypeptide, essentially comprising one of the following amino acid sequences:  
amino acids 1-437 of sequence No. 2;  
amino acids 1-409 of sequence No. 2;  
10 amino acids 1-401 of sequence No. 2;  
amino acids 22-437 of sequence No. 2;  
amino acids 22-409 of sequence No. 2;  
amino acids 22-401 of sequence No. 2;  
or a fragment thereof containing at least 50 amino  
15 acids.
2. A polypeptide, essentially consisting of one of the following amino acid sequences:  
amino acids 1-409 of sequence No. 2;  
20 amino acids 1-401 of sequence No. 2;  
amino acids 22-409 of sequence No. 2;  
amino acids 22-401 of sequence No. 2.
3. An antibody against a polypeptide of claim 1.
- 25 4. An antibody as claimed in claim 3, characterized in that it is a monoclonal antibody.
5. A process for detecting polycythemia vera,  
30 characterized in that the PRV-1 polypeptide is reacted, in an immunoassay, with one or more antibodies as claimed in claim 3 or 4.
6. A process as claimed in claim 5, characterized in  
35 that the antibody employed is a polyclonal or monoclonal antibody as claimed in claim 3 or 4.
7. A drug for treating polycythemia vera, characterized in that, in addition to customary

excipients, it comprises antibodies as claimed in claim 3 or 4.

8. A drug which comprises a polypeptide as claimed in claim 1 or a polypeptide which essentially comprises one of the following amino acid sequences:

amino acids 1-437 of sequence No. 2;  
amino acids 1-409 of sequence No. 2;  
10 amino acids 1-401 of sequence No. 2;  
amino acids 22-437 of sequence No. 2;  
amino acids 22-409 of sequence No. 2;  
amino acids 22-401 of sequence No. 2;  
and at least one pharmaceutically tolerated  
15 excipient.

9. A drug which comprises a polynucleotide which essentially comprises one of the following nucleotide sequences:

20 nucleotides 1-1600 of sequence No. 1;  
nucleotides 36-1346 of sequence No. 1;  
nucleotides 36-1262 of sequence No. 1;  
nucleotides 36-1238 of sequence No. 1;  
nucleotides 39-1346 of sequence No. 1;  
25 nucleotides 39-1262 of sequence No. 1;  
nucleotides 39-1238 of sequence No. 1;  
nucleotides 99-1346 of sequence No. 1;  
nucleotides 99-1262 of sequence No. 1;  
nucleotides 99-1238 of sequence No. 1;  
30 and at least one pharmaceutically tolerated  
excipient.

10. The use of a polypeptide as claimed in claim 1 or of a polypeptide which essentially comprises one  
35 of the following amino acid sequences:

amino acids 1-437 of sequence No. 2;  
amino acids 1-409 of sequence No. 2;  
amino acids 1-401 of sequence No. 2;  
amino acids 22-437 of sequence No. 2;

- 25 -

amino acids 22-409 of sequence No. 2;  
amino acids 22-401 of sequence No. 2;  
or of a biologically active fragment thereof or a  
biologically active variant thereof, as a growth  
factor.

11. The use of a polypeptide as claimed in claim 1 or  
of a polypeptide which essentially comprises one  
of the following amino acid sequences:
- 10 amino acids 1-437 of sequence No. 2;  
amino acids 1-409 of sequence No. 2;  
amino acids 1-401 of sequence No. 2;  
amino acids 22-437 of sequence No. 2;  
amino acids 22-409 of sequence No. 2;  
15 amino acids 22-401 of sequence No. 2;  
or of a biologically active fragment thereof or a  
biologically active variant thereof, for producing  
a drug for treating pancytopenias and  
pancytopathies in the bone marrow and in the  
20 circulation.

12. The use of a polynucleotide which essentially  
comprises one of the following nucleotide  
sequences:
- 25 nucleotides 1-1600 of sequence No. 1;  
nucleotides 36-1346 of sequence No. 1;  
nucleotides 36-1262 of sequence No. 1;  
nucleotides 36-1238 of sequence No. 1;  
nucleotides 39-1346 of sequence No. 1;  
30 nucleotides 39-1262 of sequence No. 1;  
nucleotides 39-1238 of sequence No. 1;  
nucleotides 99-1346 of sequence No. 1;  
nucleotides 99-1262 of sequence No. 1;  
nucleotides 99-1238 of sequence No. 1;  
35 or of a fragment thereof or a variant thereof, for  
producing a drug for treating pancytopenias and  
pancytopathies in the bone marrow and in the  
circulation.

13. The use of a polypeptide as claimed in claim 1 or of a polypeptide which essentially comprises one of the following amino acid sequences:  
amino acids 1-437 of sequence No. 2;  
5 amino acids 1-409 of sequence No. 2;  
amino acids 1-401 of sequence No. 2;  
amino acids 22-437 of sequence No. 2;  
amino acids 22-409 of sequence No. 2;  
amino acids 22-401 of sequence No. 2;  
10 or of a biologically active fragment thereof or a biologically active variant thereof, for treating and/or multiplying endogenous cells and/or established cell lines ex vivo or in vitro.
- 15 14. The use of a polypeptide as claimed in claim 1 or of a polypeptide which essentially comprises one of the following amino acid sequences:  
amino acids 1-437 of sequence No. 2;  
amino acids 1-409 of sequence No. 2;  
20 amino acids 1-401 of sequence No. 2;  
amino acids 22-437 of sequence No. 2;  
amino acids 22-409 of sequence No. 2;  
amino acids 22-401 of sequence No. 2;  
or of a biologically active fragment thereof or a  
25 biologically active variant thereof, for inhibiting the growth of cells.
15. The use as claimed in claim 14, characterized in that the polypeptide is used as a cytostatic  
30 agent.
16. The use of a polypeptide as claimed in claim 1 or of a polypeptide which essentially comprises one of the following amino acid sequences:  
35 amino acids 1-437 of sequence No. 2;  
amino acids 1-409 of sequence No. 2;  
amino acids 1-401 of sequence No. 2;  
amino acids 22-437 of sequence No. 2;  
amino acids 22-409 of sequence No. 2;

amino acids 22-401 of sequence No. 2;  
or of a biologically active fragment thereof or a  
biologically active variant thereof, for producing  
a drug for treating proliferative diseases.

5

17. The use as claimed in claim 16, characterized in that the proliferative disease is selected from the group comprising myeloproliferative diseases, p. vera, essential thrombocythemia, myelofibrosis, CML, all leukemias and lymphomas and also solid tumors.

15

18. The use of a polynucleotide which essentially comprises one of the following nucleotide sequences:

20

nucleotides	1-1600	of sequence No. 1;
nucleotides	36-1346	of sequence No. 1;
nucleotides	36-1262	of sequence No. 1;
nucleotides	36-1238	of sequence No. 1;
nucleotides	39-1346	of sequence No. 1;
nucleotides	39-1262	of sequence No. 1;
nucleotides	39-1238	of sequence No. 1;
nucleotides	99-1346	of sequence No. 1;
nucleotides	99-1262	of sequence No. 1;
nucleotides	99-1238	of sequence No. 1;

or of a fragment thereof or a variant thereof, for inhibiting the growth of cells.

30

19. The use of a polynucleotide which essentially comprises one of the following nucleotide sequences:

35

nucleotides 1-1600 of sequence No. 1;  
nucleotides 36-1346 of sequence No. 1;  
nucleotides 36-1262 of sequence No. 1;  
nucleotides 36-1238 of sequence No. 1;  
nucleotides 39-1346 of sequence No. 1;  
nucleotides 39-1262 of sequence No. 1;  
nucleotides 39-1238 of sequence No. 1;  
nucleotides 99-1346 of sequence No. 1;





- 29 -

or a biologically active fragment thereof or a  
biologically active variant thereof  
and/or  
at least one antibody as claimed in claim 3 or 4.

5

22. A kit for detecting the PRV-1 protein as claimed in  
claim 21, characterized in that it is an ELISA test  
kit.

10

23. A kit as claimed in claim 21 for detecting PRV-1  
mRNA, characterized in that it is a  
semiquantitative or quantitative RT-PCR analysis  
kit.

15

24. A kit as claimed in claim 21 for detecting  
PRV-1 mRNA, characterized in that it is a Northern  
blot kit.

Freiburg University Hospital Complex

Abstract

This document describes a nucleotide sequence which encodes the PRV-1 protein, and essentially comprises the sequence ID No. 1, and also a process for detecting this gene [lacuna] the mRNA coded by this gene and the polypeptide encoded by this gene.

## Freiburg University Hospital Complex

AAAAGCAGAAAGAGATTACCAGCCACAGACGGGTCAAGAGCGGGTATTACTGCTGGCCCTCC  
TGGGGTTCATCTCCCACTGCCAGGAGTGCAGGCGCTGCTCTGCCAGTTTGGGACAGTTCAGC  
ATGTGTGGAAGGTGTCCGACCTGCCCCGGCAATGGACCCCTAAGAACACCAGCTGCGACAGCG  
GCTTGGGGTGCCAGGACACGTTGATGCTCATTGAGAGCGGACCCCAAGTGAGCCTGGTGCTCT  
CCAAGGGGTGCACGGAGGCCAAGGACCAGGAGCCCCGCGTCACTGAGCACCGGATGGGCCCCG  
GCCTCTCCCTGATCTCCTACACCTTCGTGTGCCGCCAGGAGGACTTCTGCAACAACCTCGTTA  
ACTCCCTCCCGCTTTGGGCCCCACAGCCCCCAGCAGACCCAGGATCCTTGAGGTGCCCAGTCT  
GCTTGCTATGGAAGGCTGTCTGGAGGGGACAACAGAAGAGATCTGCCCCAAGGGGACCACAC  
ACTGTTATGATGGCTCCTCAGGCTCAGGGGAGGAGGCATCTTCTCCAATCTGAGAGTCCAGG  
GATGCATGCCCCAGCCAGGTGCAACCTGCTCAATGGGACACAGGAAATTGGGCCCCGTGGGTA  
TGACTGAGAACTGCAATAGGAAAGATTTCTGACCTGTCATCGGGGGACCACCATTATGACAC  
ACGGAAACTTGGCTCAAGAACCCACTGATTGGACCACATCGAATACCGAGATGTGCGAGGTGG  
GGCAGGTGTGTGAGGAGACGCTGTGTGCTCATAGATGTAGGACTCACATCAACCCTGGTGGGGA  
CAAAAGGCTGCAGCACTGTTGGGGCTCAAAATTCCCAGAAGACCACCATCCACTCAGCCCCCTC  
CTGGGGTGCTTGTGGCCTCCTATACCCACTTCTGCTCCTCGGACCTGTGCAATAGTGCCAGCA  
GCAGCAGCGTTCTGCTGAACTCCCTCCCTCCTCAAGCTGCCCCGTGCCAGGAGACCGGCAGT  
GTCCTACCTGTGTGCAGCCCCCTTGGAACTGTTCAGTGGCTCCCCCGAATGACCTGCCCCA  
GGGGCGCCACTCATTGTTATGATGGGTACATTCTCTCAGGAGGTGGGCTGTCCACCAAAA  
TGAGCATTCAAGGGCTGCGTGGCCCAACCTTCCAGCTTCTTGTGAACCACACCAGACAAATCG  
GGATCTTCTCTGCGCGTGAGAAGCGTGATGTGCAGCCTCCTGCCTCTCAGCATGAGGGAGGTG  
GGGCTGAGGGCCTGGAGTCTCTCACTTGGGGGGTGGGGCTGGCACTGGCCCCAGCGCTGTGGT  
GGGGAGTGGTTTGGCCTTCCCTGCTAACTCTATTACCCCCACGATTCTTCACCGCTGCTGACCA  
CCCACACTCAACCTCCCTCTGACCTCATAACCTAATGGCCTTGGACACCAGATTCTTTCCCAT  
TCTGTCCATGAATCATCTTCCCCACACAAATCATATCTACTCACCTAACAGCAACACT  
GGGGAGAGCCTGGAGCATCCGGACTTGCCCTATGGGAGAGGGGACGCTGGAGGAGTGGCTGCA  
TGTATCTGATAATACAGACCCTGTC

Fig. 1

## Freiburg University Hospital Complex

MSAVLLLALLGFILPLPGVQA---LLCQFGTVQHVKVSDLPRQWTPKNTSCD  
SGLGCQDTLMLIESGPQVSLVLSKGCTEAKDQEPRVTEHRMGPGLSLISY  
TFVCRQEDFCNNLVNSLPLWAPQPPADPGSLRCPVCLSMEGCLEGTTEEI  
CPKGTTHCYDGLLRRLRGGGIFS NLRVQGCMPPGCGNLLNGTQEIGPVGMT  
ENCNRKDFLTCHRGTTIMTHGNLAQEPTDWTTSENTEMCEVGQVCQETLLL  
IDVGLTSTLVGTKGCSTVGAQNSQKTTIHSAPPGVLVASYTHFCSSDLN  
SASSSSVLLNSLPPQAAPVPGDRQCPTCVQPLGTCSSGSPRMTCPRGATH  
CYDGYIHLSGGGLSTKMSIQGCVAQPSSFLLNHTRQIGIFSAREKRDVQP  
PASQHEGGGAEGLES LTWGVGLALAPALWVGVCPCSC

Fig. 2

As a below named inventor, I hereby declare that:

\_\_\_\_\_ is attached hereto.  
  X   was filed on September 29, 2000 ✓  
as United States Application Number \_\_\_\_\_  
or PCT International Application Number PCT/EP00/09594 ✓

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above. I do not know and do not believe that the claimed invention was ever known or used in the United States of America before my invention thereof, or patented or described in any printed publication in any country before my invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, and that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months (for a utility patent application) or six months (for a design patent application) prior to this application.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d), of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

<u>19947010.3</u> ✓ (Number)	<u>DE - Germany</u> ✓ (Country)	<u>30-September-1999</u> ✓ (Day/Month/Year Filed)	<u>X</u> Yes	<u>    </u> No
<u>PCT/EP00/09594</u> ✓ (Number)	<u>WO - PCT</u> ✓ (Country)	<u>29-September-2000</u> ✓ (Day/Month/Year Filed)	<u>X</u> Yes	<u>    </u> No
<u>                    </u> (Number)	<u>                    </u> (Country)	<u>                    </u> (Day/Month/Year Filed)	<u>    </u> Yes	<u>    </u> No

(Application Number)	Filing Date
----------------------	-------------

(Application Number)	Filing Date	(Status – patented, pending, abandoned)
----------------------	-------------	-----------------------------------------

[illegible]

(Application Number)	Filing Date	(Status – patented, pending, abandoned)
----------------------	-------------	-----------------------------------------

TransPotomac Plaza  
1033 N. Fairfax St., Suite 306  
Alexandria, VA 22314

with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith.

The undersigned hereby authorizes the U.S. Attorneys named herein to accept and follow instructions from undersigned's assignee, if any, and/or, if the undersigned is not a resident of the United States, the undersigned's domestic attorney, patent attorney or patent agent, as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and the undersigned. In the event of a change in the person(s) from whom instructions may be taken, the U.S. attorneys named herein will be so notified by the undersigned.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application of any patent issued thereon.

Full Name of Sole/First Inventor: PAHL, Heike

Inventor's Signature: William L. Gabel Date: 26.3.02

Residence: Freiburg DE (City, State)      Citizenship: Germany (Country) ✓

Post Office Address: Spargelweg 32, 79112 Freiburg, GERMANY

10089503 - 04-2-902

Rec'd PCT/PTO 29 APR 2002

10/089503

## SEQUENCE LISTING

<110> Universitätsklinikum Freiburg  
<120> THE PRV-1 GENE AND USE THEREOF  
<130> E980930  
<140> PCT/EP00/09594  
<141> 2000-09-29  
<150> DE 199 47 010.3  
<151> 1999-09-30  
<160> 10  
<170> PADAT Sequenzmodul, Version 1.0

<210> 1  
<211> 1600  
<212> DNA  
<213> homo sapiens

<220>  
<223>

<400> 1

aaaagcagaa agagattacc agccacagac gggtcattgag cgcgggtatta ctgctggccc	60
tcctgggggtt catcctccca ctgccaggag tgcaggcgct gctctgccag tttgggacag	120
ttcagcatgt gtggaagggtg tccgacctgc cccggcaatg gacccctaag aacaccagct	180
gcgacagcgg cttgggggtgc caggacacgt tgatgctcat tgagagcgga cccaagtga	240
gcctgggtgct ctccaagggtc tgcacggagg ccaaggacca ggagccccgc gtcactgagc	300
accggatggg ccccgccctc tccctgatct cctacacctt cgtgtgccgc caggaggact	360
tctgcaacaa cctcgtaaac tccctccgc tttgggcccc acagcccca gcagaccag	420
gatccttgag gtgcccagtc tgcttgctta tggaaggctg tctggagggg acaacagaag	480
agatctgccc caaggggacc acacactgtt atgatggcct cctcaggctc aggggaggag	540
gcatcttctc caatctgaga gtccagggat gcatgcccc gccagggtgc aacctgtca	600
atgggacaca ggaaattggg cccgtgggta tgactgagaa ctgcaatagg aaagattttc	660
tgacctgtca tcgggggacc accattatga cacacggaaa cttgggtcaa gaaccactg	720
attggaccac atcgaatacc gagatgtgcg aggtggggca ggtgtgtcag gagacgtgc	780
tgctcataga tgtaggactc acatcaacc tggtggggac aaaaggctgc agcactgttg	840
gggtcaaaa ttcccagaag accaccatcc actcagcccc tcctgggggtg cttgtggcct	900
cctataccca cttctgctcc tcggacctgt gcaatagtgc cagcagcagc agcgttctgc	960
tgaactccct ccctcctcaa gctgccccctg tcccaggaga ccggcagtgt cctacctgtg	1020
tgcagcccct tggaacctgt tcaagtggct ccccccgaat gacctgcccc aggggcgcca	1080
ctcattgtta tgatgggtac attcatctct caggagggtg gctgtccacc aaaatgagca	1140
ttcagggtg cgtggcccaa cttccagct tcttgttgaa ccacaccaga caaatcggga	1200
tcttctctgc gcgtgagaag cgtgatgtgc agcctcctgc ctctcagcat gagggagggtg	1260

gggctgaggg cctggagtct ctcacttggg ggggtggggct ggcactggcc ccagcgctgt 1320  
 ggtggggagt ggtttgccct tcctgctaac tctattaccc ccacgattct tcaccgctgc 1380  
 tgaccaccca cactcaacct cctctgacc tcataaccta atggccttgg acaccagatt 1440  
 ctttccatt ctgtccatga atcatcttcc ccacacacaa tcattcatat ctactcacct 1500  
 aacagcaaca ctggggagag cctggagcat ccggacttgc cctatgggag aggggacgct 1560  
 ggaggagtgg ctgcatgtat ctgataatac agaccctgtc 1600

<210> 2  
 <211> 437  
 <212> PRT  
 <213> homo sapiens  
 <400> 2

Met Ser Ala Val Leu Leu Leu Ala Leu Leu Gly Phe Ile Leu Pro Leu  
 1 5 10 15  
 Pro Gly Val Gln Ala Leu Leu Cys Gln Phe Gly Thr Val Gln His Val  
 20 25 30  
 Trp Lys Val Ser Asp Leu Pro Arg Gln Trp Thr Pro Lys Asn Thr Ser  
 35 40 45  
 Cys Asp Ser Gly Leu Gly Cys Gln Asp Thr Leu Met Leu Ile Glu Ser  
 50 55 60  
 Gly Pro Gln Val Ser Leu Val Leu Ser Lys Gly Cys Thr Glu Ala Lys  
 65 70 75 80  
 Asp Gln Glu Pro Arg Val Thr Glu His Arg Met Gly Pro Gly Leu Ser  
 85 90 95  
 Leu Ile Ser Tyr Thr Phe Val Cys Arg Gln Glu Asp Phe Cys Asn Asn  
 100 105 110  
 Leu Val Asn Ser Leu Pro Leu Trp Ala Pro Gln Pro Pro Ala Asp Pro  
 115 120 125  
 Gly Ser Leu Arg Cys Pro Val Cys Leu Ser Met Glu Gly Cys Leu Glu  
 130 135 140  
 Gly Thr Thr Glu Glu Ile Cys Pro Lys Gly Thr His Cys Tyr Asp  
 145 150 155 160  
 Gly Leu Leu Arg Leu Arg Gly Gly Ile Phe Ser Asn Leu Arg Val  
 165 170 175  
 Gln Gly Cys Met Pro Gln Pro Gly Cys Asn Leu Leu Asn Gly Thr Gln  
 180 185 190  
 Glu Ile Gly Pro Val Gly Met Thr Glu Asn Cys Asn Arg Lys Asp Phe  
 195 200 205  
 Leu Thr Cys His Arg Gly Thr Thr Ile Met Thr His Gly Asn Leu Ala  
 210 215 220  
 Gln Glu Pro Thr Asp Trp Thr Thr Ser Asn Thr Glu Met Cys Glu Val  
 225 230 235 240  
 Gly Gln Val Cys Gln Glu Thr Leu Leu Ile Asp Val Gly Leu Thr  
 245 250 255  
 Ser Thr Leu Val Gly Thr Lys Gly Cys Ser Thr Val Gly Ala Gln Asn  
 260 265 270  
 Ser Gln Lys Thr Thr Ile His Ser Ala Pro Pro Gly Val Leu Val Ala  
 275 280 285  
 Ser Tyr Thr His Phe Cys Ser Ser Asp Leu Cys Asn Ser Ala Ser Ser  
 290 295 300  
 Ser Ser Val Leu Leu Asn Ser Leu Pro Pro Gln Ala Ala Pro Val Pro  
 305 310 315 320  
 Gly Asp Arg Gln Cys Pro Thr Cys Val Gln Pro Leu Gly Thr Cys Ser  
 325 330 335  
 Ser Gly Ser Pro Arg Met Thr Cys Pro Arg Gly Ala Thr His Cys Tyr  
 340 345 350  
 Asp Gly Tyr Ile His Leu Ser Gly Gly Gly Leu Ser Thr Lys Met Ser  
 355 360 365  
 Ile Gln Gly Cys Val Ala Gln Pro Ser Ser Phe Leu Leu Asn His Thr  
 370 375 380  
 Arg Gln Ile Gly Ile Phe Ser Ala Arg Glu Lys Arg Asp Val Gln Pro  
 385 390 395 400





<223> RT-Primer

<400> 7

attaggttat gaggtcagag ggaggtt

27

<210> 8

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> sense-Primer

<400> 8

gcagaaagag attaccagcc acagacgg

28

<210> 9

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> antisense-Primer

<400> 9

gaatcgtggg ggtaatagag ttagcagg

28

<210> 10

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> probe

<400> 10

ttcttgttga accacaccag acaaatcgg

29